Literature DB >> 11022787

Immune escape by hepatitis B viruses.

U Protzer1, H Schaller.   

Abstract

Hepatitis B viruses are DNA viruses characterized by their very small genome size and their unique replication via reverse transcription. The circular genome has been efficiently exploited, thereby limiting genome variation, and leaves no space for genes in addition to those essentially needed during the viral live cycle. Hepatitis B viruses are prototype non-cytopathic viruses causing persistent infection. Human hepatitis B virus (HBV), as well as the closely related animal viruses, most frequently are transmitted vertically from mothers to their offspring. Because infection usually persists for many years, if not lifelong, hepatitis B viruses need efficient mechanisms to hide from the immune response of the host. To escape the immune response, they exploit different strategies. Firstly, they use their structural and non-structural proteins multiplely. One of the purposes is to alter the immune response. Secondly, they replicate by establishing a pool of stable extrachromosomal transcription templates, which allow the virus to react sensitively to changes in its microenvironment by up- or downregulating gene expression. Thirdly, hepatitis B viruses replicate in the liver which is an immunopriviledged site.

Entities:  

Mesh:

Year:  2000        PMID: 11022787

Source DB:  PubMed          Journal:  Virus Genes        ISSN: 0920-8569            Impact factor:   2.332


  101 in total

1.  A pretransplant infection with precore mutants of hepatitis B virus does not influence the outcome of orthotopic liver transplantation in patients on high dose anti-hepatitis B virus surface antigen immunoprophylaxis.

Authors:  U Naumann; U Protzer-Knolle; T Berg; K Leder; H Lobeck; W O Bechstein; G Gerken; U Hopf; P Neuhaus
Journal:  Hepatology       Date:  1997-08       Impact factor: 17.425

2.  Specific cytotoxic T cells eliminate B cells producing virus-neutralizing antibodies [corrected].

Authors:  O Planz; P Seiler; H Hengartner; R M Zinkernagel
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

Review 3.  Viral mutations, TCR antagonism and escape from the immune response.

Authors:  A Franco; C Ferrari; A Sette; F V Chisari
Journal:  Curr Opin Immunol       Date:  1995-08       Impact factor: 7.486

4.  Hepatitis B virus envelope variation after transplantation with and without hepatitis B immune globulin prophylaxis.

Authors:  W F Carman; C Trautwein; F J van Deursen; K Colman; E Dornan; G McIntyre; J Waters; V Kliem; R Müller; H C Thomas; M P Manns
Journal:  Hepatology       Date:  1996-09       Impact factor: 17.425

5.  Expression of the terminal protein region of hepatitis B virus inhibits cellular responses to interferons alpha and gamma and double-stranded RNA.

Authors:  G R Foster; A M Ackrill; R D Goldin; I M Kerr; H C Thomas; G R Stark
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

6.  Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

Authors:  M G Ghany; B Ayola; F G Villamil; R G Gish; S Rojter; J M Vierling; A S Lok
Journal:  Hepatology       Date:  1998-01       Impact factor: 17.425

7.  Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.

Authors:  A Bertoletti; A Sette; F V Chisari; A Penna; M Levrero; M De Carli; F Fiaccadori; C Ferrari
Journal:  Nature       Date:  1994-06-02       Impact factor: 49.962

8.  Lamivudine therapy of WHV-infected woodchucks.

Authors:  W S Mason; J Cullen; G Moraleda; J Saputelli; C E Aldrich; D S Miller; B Tennant; L Frick; D Averett; L D Condreay; A R Jilbert
Journal:  Virology       Date:  1998-05-25       Impact factor: 3.616

Review 9.  Hepatitis B virus transgenic mice: models of viral immunobiology and pathogenesis.

Authors:  F V Chisari
Journal:  Curr Top Microbiol Immunol       Date:  1996       Impact factor: 4.291

10.  T-cell tolerance: exposure to virus in utero does not cause a permanent deletion of specific T cells.

Authors:  B D Jamieson; R Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

View more
  7 in total

Review 1.  The underlying mechanisms for the "simultaneous HBsAg and anti-HBs serological profile".

Authors:  R A A Pondé
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-04-12       Impact factor: 3.267

2.  Hepatitis C virus-cross-reactive TCR gene-modified T cells: a model for immunotherapy against diseases with genomic instability.

Authors:  Timothy T Spear; Timothy P Riley; Gretchen E Lyons; Glenda G Callender; Jeffrey J Roszkowski; Yuan Wang; Patricia E Simms; Gina M Scurti; Kendra C Foley; David C Murray; Lance M Hellman; Rachel H McMahan; Makio Iwashima; Elizabeth Garrett-Mayer; Hugo R Rosen; Brian M Baker; Michael I Nishimura
Journal:  J Leukoc Biol       Date:  2016-02-26       Impact factor: 4.962

3.  Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice.

Authors:  Kelly R Long; Elena Lomonosova; Qilan Li; Nathan L Ponzar; Juan A Villa; Erin Touchette; Stephen Rapp; R Matt Liley; Ryan P Murelli; Alexandre Grigoryan; R Mark Buller; Lisa Wilson; John Bial; John E Sagartz; John E Tavis
Journal:  Antiviral Res       Date:  2017-11-10       Impact factor: 5.970

4.  Reduced hepatitis B virus (HBV)-specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy.

Authors:  J Judy Chang; Fiona Wightman; Angeline Bartholomeusz; Anna Ayres; Stephen J Kent; Joseph Sasadeusz; Sharon R Lewin
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

5.  Pre-s1 antigen-dependent infection of Tupaia hepatocyte cultures with human hepatitis B virus.

Authors:  Dieter Glebe; Mehriar Aliakbari; Peter Krass; Eva V Knoop; Klaus P Valerius; Wolfram H Gerlich
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

6.  Effects of Zhaoyangwan on chronic hepatitis B and posthepatic cirrhosis.

Authors:  Cui-Ping Zhang; Zi-Bin Tian; Xi-Shuang Liu; Qing-Xi Zhao; Jun Wu; Yong-Xin Liang
Journal:  World J Gastroenterol       Date:  2004-01-15       Impact factor: 5.742

7.  Can engineered "designer" T cells outsmart chronic hepatitis B?

Authors:  U Protzer; H Abken
Journal:  Hepat Res Treat       Date:  2010-09-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.